A new approach to change lymphoid leukemia cells
A novel strategy for transcriptional reprogramming of lymphoid leukemia cells
This study is looking at a new way to help certain types of leukemia cells grow up and die off like they should, which could lead to better treatments for people with B-cell and T-cell leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11003688 on NIH RePORTER |
What this research studies
This research investigates a novel strategy to reprogram lymphoid leukemia cells, specifically targeting B-cell acute lymphoblastic leukemia (B-ALL) and T-cell lymphoblastic leukemia (TCLL). The approach focuses on understanding and overcoming the barriers that prevent these cancer cells from maturing and undergoing apoptosis, which is a natural process of cell death. By exploring the mechanisms of transcriptional reprogramming, the research aims to induce differentiation in leukemic cells, potentially leading to more effective treatments. Patients may benefit from therapies that utilize all-trans-retinoic acid and arsenic trioxide, which have shown limited success in the past.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with B-ALL or TCLL who have not responded adequately to existing treatments.
Not a fit: Patients with other types of leukemia or those who have already achieved remission may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with lymphoid leukemia, improving their chances of recovery.
How similar studies have performed: While the concept of transcriptional reprogramming has been explored, this specific approach is novel and aims to address previously unmet challenges in treating lymphoid leukemia.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Calabretta, Bruno — Thomas Jefferson University
- Study coordinator: Calabretta, Bruno
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.